1. Home
  2. MHF vs BDTX Comparison

MHF vs BDTX Comparison

Compare MHF & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Municipal High Income Fund Inc.

MHF

Western Asset Municipal High Income Fund Inc.

HOLD

Current Price

$6.80

Market Cap

153.1M

Sector

Finance

ML Signal

HOLD

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$1.75

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MHF
BDTX
Founded
1988
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.1M
171.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
MHF
BDTX
Price
$6.80
$1.75
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$9.67
AVG Volume (30 Days)
73.2K
1.2M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
4.29%
N/A
EPS Growth
N/A
130.71
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.63
$1.60
52 Week High
$7.64
$4.94

Technical Indicators

Market Signals
Indicator
MHF
BDTX
Relative Strength Index (RSI) 32.66 42.48
Support Level $6.63 $1.76
Resistance Level $7.05 $2.26
Average True Range (ATR) 0.11 0.10
MACD -0.03 0.01
Stochastic Oscillator 3.95 7.14

Price Performance

Historical Comparison
MHF
BDTX

About MHF Western Asset Municipal High Income Fund Inc.

Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: